
Muvalaplin 是一種新型口服藥物，經臨床試驗證實，能安全有效地降低 Lp(a) 水平，為治療高 Lp(a) 水平帶來新希望。


coremsg

Muvalaplin shows promise in lowering lipoprotein(a) levels, which are genetically determined and confer cardiovascular risk and for which no approved therapies currently exist.

New Pill Successfully Lowers Lp(a) Levels

新型口服藥物-muvalaplin-成功降低-lp-a-水平


新型口服藥物 Muvalaplin 成功降低 Lp(a) 水平
